Introduction {#Sec1}
============

With refinements in technology, extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) in general now represent a significant development in intensive care practice \[[@CR1]--[@CR4]\]. A wide range of acutely ill patients with cardiorespiratory failure are now being successfully rescued with ECLS therapies, but clinicians await definitive evidence supporting their use. Invasive ECLS therapies such as ECMO are complex supportive interventions, and outcomes rely not only on technology but also on user experience \[[@CR5]\]; optimisation of other aspects of intensive care unit (ICU) management, established processes and other available services in each centre; and optimisation of pharmacotherapy to minimise and/or treat complications \[[@CR6]\].

A variety of infectious and non-infectious conditions may result in severe cardiorespiratory failure, and an infection or sepsis is no longer considered a contraindication for ECMO \[[@CR7]\]. Similarly, patients on ECMO may develop a variety of ICU-acquired infections that may necessitate antimicrobial therapy. Optimal antimicrobial therapy in these patients is a balance between potency, bacterial susceptibility and exposure \[[@CR8], [@CR9]\]. The authors of a recent review identified 30.1 infections per 1000 days of ECMO among patients with infections who were experiencing prolonged ICU and hospital lengths of stay \[[@CR10]\]. The authors of another review \[[@CR11]\] identified a total of 2418 infections in 20,741 (12 %) ECMO cases, with increased morbidity seen in patients with infections. Antimicrobial therapy is commonly prescribed in ECMO patients, and optimisation of dosing is central not only to improving patient outcomes but also to minimising the emergence of microbial resistance \[[@CR8]\].

However, ECMO is known to induce significant pharmacokinetic (PK) alterations \[[@CR12]\] in critically ill patients who already exhibit significantly altered PK \[[@CR13]\], raising concerns of therapeutic failure or toxicity. Neonatal studies have shown major variations in antibiotic PK during ECMO \[[@CR12], [@CR14]--[@CR16]\], and there is an emerging body of literature to support this in adult patients \[[@CR17]--[@CR20]\]. The interaction between the drug, the ECMO device and the disease are complex; hence clinical population PK studies alone may not be able to advance understanding of mechanisms behind altered PK in ECMO patients. This calls for systematic investigation \[[@CR21]\] of each of these factors. To this end, experimental studies \[[@CR22], [@CR23]\] using circuit components used in adults have shown significant drug sequestration in ECMO circuits based on physicochemical properties of the drug, such as drug stability, octanol-water coefficient (logP, a marker of lipophilicity) and protein binding (PB).

Ex vivo experimental conditions are quite different from in vivo scenarios. The addition of an extracorporeal circuit to a critically ill patient may result in profound PK alterations, and appreciating the relative contributions of drug, device and disease factors to altered PK is challenging. Building on the data derived from ex vivo circuit studies, we aimed to develop PK models for antibiotic study drugs that exhibit wide a range of logP and PB in ambulatory healthy sheep (HS) as well as in healthy and critically ill sheep on ECMO. We hypothesised that the drug properties logP and PB can be used to predict PK alterations of antimicrobial drugs during ECMO.

Methods {#Sec2}
=======

Ethical approval was obtained from the Queensland University of Technology Animal Ethics Committee (approval number 1100000053) and the University of Queensland Animal Ethics Committee (approval number QUT/194/12). All experimentation was done in accordance with the National Health and Medical Research Council's Australian Code for the Care and Use of Animals for Scientific Purposes, Eighth Edition (2013) (<https://www.nhmrc.gov.au/book/australian-code-care-and-use-animals-scientific-purposes-8th-edition-2013>).

Pharmacokinetic sampling {#Sec3}
------------------------

### Healthy ambulatory sheep {#Sec4}

Seven HS weighing 46--51 kg were housed in a metabolic cart amongst a larger flock, with free access to food and water. Two three-lumen central venous catheters were inserted in the left and right internal jugular veins (IJVs) while the animals were under local anaesthesia for drug administration and PK sampling. The catheters were secured with adhesive glue and a sleeve dressing around the neck. Study drugs were infused for 30 minutes, and serial blood samples were obtained for drug assays using validated chromatographic methods and subsequent PK analysis.

### Healthy sheep on ECMO {#Sec5}

We performed PK sampling in seven healthy sheep on extracorporeal membrane oxygenation (E24H). A detailed description of our ovine model of venovenous ECMO is provided elsewhere \[[@CR21], [@CR24]\]. Briefly, a central venous line was placed in the right IJV while the animals were under local anaesthesia. Alfaxalone, ketamine and midazolam were used for induction and maintenance of anaesthesia. Buprenorphine 0.01 mg/kg was used for supplemental analgesia. Sheep were intubated and ventilated with a Hamilton Galileo ventilator (Hamilton Medical AG, Bonaduz, Switzerland). The facial artery was cannulated for invasive arterial blood pressure monitoring. A pulmonary arterial catheter provided continuous measurements of central venous pressure, mixed venous oxygen saturation and continuous cardiac output (CCO).

Cannulation for ECMO was performed with the animals in supine position. A 21-French (50 cm) CARMEDA BioActive Surface--coated (CBAS®; Carmeda, Upplands Väsby, Sweden) venous cannula (Medtronic, Minneapolis, MN, USA) was inserted into the right IJV using a Seldinger technique and positioned using intra-cardiac echocardiography (ICE) \[[@CR25]\] in the proximal inferior vena cava. A 19-French (50 cm) CARMEDA-coated femoral venous cannula was used for return blood and was inserted in the right IJV and positioned at the superior vena cava right atrium using ICE. ECMO pump speeds were titrated to target flows at least two-thirds of pre-ECMO CCO (or 60--80 ml/kg). Immediately upon commencement of ECMO, study drugs were infused for 30 minutes and serial blood samples were obtained for drug assays using validated chromatographic methods and subsequent PK analysis.

### Smoke inhalation acute lung injury sheep on ECMO {#Sec6}

We performed PK sampling in six sheep with smoke inhalation acute lung injury on ECMO (SE24H). The anaesthesia and ECMO techniques we used are described in the previous section. Smoke inhalation acute lung injury (S-ALI) was induced using a validated, reproducible technique previously published \[[@CR26]\]. Briefly, a stainless steel plate was heated to 750 °C and placed on top of 8 g of cotton in a cup. The smoke resulting from combustion collected in the bellows of the purpose-built device was delivered to the sheep by manual compression (tidal volume \[V~T~\], 10--12 ml/kg) to achieve a carboxyhaemoglobin content of 45--50 %. The sheep were ventilated using Acute Respiratory Distress Syndrome Network criteria (V~T~ 4--6 ml/kg, positive end-expiratory pressure 10--15 cm H~2~O) for lung-protective ventilation \[[@CR27]\]. Once ECMO was established, study drugs were infused for 30 minutes and serial blood samples were obtained for drug assays using validated chromatographic methods and subsequent PK analysis.

Study drugs, drug administration and pharmacokinetic sampling {#Sec7}
-------------------------------------------------------------

Following baseline sampling, study drugs in identical doses were administered to the HS, E24H and SE24H groups. The chosen anti-infective study drugs exhibit a wide range of logP and PB (Table [1](#Tab1){ref-type="table"}). The intravenous (IV) study drugs (doses, administration techniques) used were meropenem (500 mg, bolus), ceftriaxone (500 mg, IV bolus), gentamicin (240 mg, slow IV bolus), vancomycin (500 mg in 50 ml 0.9 % saline, IV for 30 minutes), fluconazole (100 mg in 50 ml of 0.9 % saline, IV for 30 minutes), caspofungin (50 mg in 100 ml of 0.9 % saline, IV for 30 minutes), ciprofloxacin (100 mg in 50 ml of 0.9 % saline, IV for 30 minutes) and doripenem (500 mg in 100 ml of 0.9 % saline, IV for 30 minutes). Serial blood samples (2 ml) were obtained at 15, 30, 45, 60, 90, 180, 360, 480 and 720 minutes after commencement of antibiotic drug infusions for drug assays and subsequent PK analysis.Table 1Lipophilicity and protein binding characteristics of study drugsStudy drugLipophilicity (logP)Protein binding (%)Ceftriaxone−1.795Ciprofloxacin2.320--40Caspofungin0.197Fluconazole0.411--12Gentamicin−3.10--30Meropenem−0.62Doripenem0.78Vancomycin−3.155A higher numeric value for octanol-water partition coefficient (logP) indicates greater lipophilicity \[[@CR29]\]

Antimicrobial drug assays {#Sec8}
-------------------------

Meropenem, doripenem, ceftriaxone and vancomycin analysis was done using high-performance liquid chromatography (HPLC) on a Prominence Ultra Fast system (Shimadzu, Kyoto, Japan) with ultraviolet light detection at 304 nm (meropenem and doripenem) and 230 nm (ceftriaxone and vancomycin). Ciprofloxacin was analysed on a Prominence HPLC system with fluorescence detection at 278 nm (excitation) and 456 nm (emission). Caspofungin, gentamicin and fluconazole analysis was carried out using liquid chromatography--tandem mass spectrometry on a Shimadzu Nexera-8030+ system with detection by positive mode multiple reaction monitoring. Samples were prepared by protein precipitation with trichloroacetic acid (ciprofloxacin and gentamicin), acetonitrile (caspofungin and fluconazole) or acetonitrile with dichloromethane washing (meropenem, ceftriaxone, vancomycin and doripenem). Chromatography was carried out using reversed-phase C18 HPLC columns (meropenem, ceftriaxone, vancomycin, doripenem, ciprofloxacin), reversed-phase C8 HPLC columns (caspofungin, fluconazole) or high-performance liquid chromatography (HPLC) (gentamicin). All methods were validated according to the guidelines of the US Food and Drug Administration \[[@CR28]\]. All samples were assayed with internal standards, alongside calibration standards and quality control samples, and met the acceptance criteria.

Statistical analysis and pharmacokinetic modelling {#Sec9}
--------------------------------------------------

Discrete variables were expressed as count (percentage) and continuous variables as mean ± SD. Demographics and clinical differences between study groups were assessed using a χ^2^ test, Fisher's exact test or Student's *t* test, as appropriate. *p* \< 0.05 was considered statistically significant.

A linear mixed effects model was used to examine changes in concentration over time whilst controlling for repeated results from the same sheep. The result adjusts for changes over time and repeated results from the same sheep. The concentration versus time curves (mean ± SEM) were plotted using GraphPad Prism version 5.03 software (GraphPad Software, La Jolla, CA, USA). PK analysis of antibiotic concentrations was undertaken using a non-compartmental approach. All statistical analyses were done using R version 3.1.2 software (R Foundation for Statistical Computing, Vienna, Austria).

We compared the statistical data between the three groups using a box plot. To look for a difference in the mean statistics between groups, we used a linear model with group as the dependent variable. Because the PK data were strongly positively skewed, we log-transformed them before building regression models. Regression models were derived to examine the differences in the following PK parameters between the three study groups: area under the curve (AUC), mean resident time, clearance (CL), steady-state volume of distribution (V~ss~), maximum plasma concentration and minimum plasma concentration. A linear regression analysis was used to predict PK parameters based on drug properties. logP data for the individual drugs are available from the University of Alberta DrugBank website \[[@CR29]\].

Results {#Sec10}
=======

We observed no complications during the ECMO run. We found no significant differences between the physiologic variables at the baseline (Table [2](#Tab2){ref-type="table"}). Differences in physiologic variables between the E24H and SE24H groups are presented in Table [3](#Tab3){ref-type="table"}. We found statistically significant differences in pH, haemodynamics, fluid balance and plasma proteins between the E24H and SE24H groups (*p* \< 0.001).Table 2Demographic and physiologic data at baseline after initiation of anaesthesia, mechanical ventilation and haemodynamic monitoring and before smoke inhalation and commencement of ECMOGroupMeanSD*p* ValueWeight, kgE24H48.54.60.84SE24H49.64.4Heart rate, beats/minE24H116130*.*78SE24H11811Mean arterial BP, mmHgE24H116*.*16*.*80*.*91SE24H115*.*78*.*1Mean PAP, mmHgE24H24*.*62*.*80*.*06SE24H21*.*23*.*2CVP, cmH~2~OE24H15*.*62*.*80*.*06SE24H12*.*23*.*2CCO, L/minE24H5*.*440*.*930*.*33SE24H5*.*030*.*46SvO~2~, %E24H78*.*87*.*10*.*31SE24H82*.*04*.*1PEEP, cmH~2~OE24H8*.*12*.*60*.*67SE24H7*.*52*.*7Respiratory rate, breaths/minE24H10*.*96*.*00*.*6SE24H12*.*55*.*2Fluid balance, mlE24H6813760*.*11SE24H92668Haemoglobin, g/LE24H7*.*01*.*20*.*47SE24H7*.*61*.*7pHE24H7*.*3850*.*0310*.*62SE24H7*.*3970*.*052Body temperature, °CE24H38*.*260*.*610*.*67SE24H38*.*130*.*50Lactate, mmol/LE24H1*.*340*.*440*.*17SE24H1*.*070*.*24Midazolam dose, mg/hE24H14*.*41*.*20*.*17SE24H15*.*00*.*0Urine output, ml/hE24H69440*.*87SE24H7468Albumin, g/LE24H37*.*162*.*530*.*33SE24H38*.*150*.*86Alanine aminotransferase (U/L)E24H11*.*72*.*10*.*51SE24H12*.*41*.*7Serum bilirubin, μmol/LE24H2*.*160*.*690*.*75SE24H2*.*030*.*74Serum creatinine, μmol/LE24H88150*.*94SE24H8711Total protein, g/LE24H71*.*76*.*40*.*78SE24H71*.*01*.*9Urine creatinine, μmol/LE24H10,17237980*.*17SE24H15,5418009*BP* blood pressure, *PAP* pulmonary arterial pressure, *CVP* central venous pressure, *CCO* continuous cardiac output, SvO~2~ mixed venous oxygen saturation, *PEEP* positive end-expiratory pressureData presented are derived from comparison of the results between groups: healthy sheep on extracorporeal membrane oxygenation (E24H) (*n* = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (SE24H) (*n* = 6)Table 3Mean differences in Physiologic parameters of E24H and SE24H groups during the pharmacokinetic sampling intervalVariableMeanLowerUpper*p* ValueHeart rate1.41−9.5412.360.815Mean arterial BP−23.83−31.35−16.25*\<*0.001Mean PAP1.77−0.834.370.234CVP0.93−3.004.860.669CCO−2.09−3.30−0.870.01SvO~2~−0.78−3.311.740.585PEEP2.090.663.520.02Respiratory rate (sheep)2.330.184.480.068Tidal volume−38.24−135.3858.870.479FiO~2~7.77−2.0417.690.151paO~2~48.050.4395.670.053paCO~2~3.12−0.286.520.115Running fluid balance4604.142779.386428.89*\<*0.001ctHb2.001.342.66*\<*0.001pH−0.07−0.10−0.030.003Body temperature−0.06−0.380.270.754Lactate0.710.261.160.013Midazolam dose per hour−5.97−21.379.420.485Urine output6.68−54.8868.250.843Albumin−14.91−16.70−13.10*\<*0.001ALT5.12−6.2516.490.419AST82.87−23.66189.390.175Bilirubin (Direct)−0.48−1.680.730.476Bilirubin (Total)−0.12−0.710.500.823Creatinine0.56−11.5212.640.933Total protein−26.60*\<*0.001Urea0.79−0.472.060.271Urine creatinine−4327.47−9508.52974.490.322*BP* blood pressure, *PAP* pulmonary arterial pressure, *CVP* central venous pressure, *CCO* continuous cardiac output, *SvO* ~*2*~ mixed venous oxygen saturation, *PEEP* positive end-expiratory pressure, *FiO* ~*2*~ fraction of inspired oxygen, *paO* ~*2*~ partial pressure of oxygen, *paCO* ~*2*~ partial pressure of carbon dioxide, *ctHb* concentration of total blood haemoglobin, *ALT* alanine aminotransferase, *AST* aspartate aminotransferaseThe analysis was carried out using a mixed model with a random intercept for each sample. The results are presented as mean difference and 95 % confidence intervals, including a linear time trend and using each sheep's baseline (time 0) as a covariate

Sixteen hundred samples were analysed for study drug concentrations. Concentration versus time curves for the study antibiotics are shown in Fig. [1](#Fig1){ref-type="fig"}. A summary of PK parameters estimated using a non-compartmental analysis is presented in Table [4](#Tab4){ref-type="table"}. Significant differences in AUC between groups were found for ciprofloxacin, gentamicin and caspofungin. For ciprofloxacin, the most lipophilic drug studied, there was a significant difference in V~ss~ between the E24H and SE24H groups (*p* = 0.004). For relatively protein-bound drugs, there was a trend towards increased V~ss~ only in the SE24H group compared with HS group. However, an increase in CL was seen in both the E24H and SE24H groups compared with the HS group for vancomycin (*p* = 0.02 for both), ceftriaxone (*p* = 0008 and *p* = 0.05, respectively) and caspofungin (*p* \< 0.001 for both), which are relatively more protein-bound.Fig. 1Concentration versus time curves for study drugs. **a** Meropenem. **b** Vancomycin. **c** Ceftriaxone. **d** Ciprofloxacin. **e** Fluconazole. **f** Doripenem. **g** Caspofungin. **h** Gentamicin. *E24H* healthy sheep on extracorporeal membrane oxygenation, *HS* healthy sheep, *SE24H* sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenationTable 4Non-compartmental pharmacokinetic estimates for eight study drugs for all three study groupsStudy drugGroupC~max~ (mg/L)C~min~ (mg/L)AUC~0--∞~ (mg/h/L)V~ss~ (L)Clearance (L/h)MRT (h)CeftriaxoneHS71 (14)0.0 (0.1)202 (46)9.0 (1.8)2.6 (0.6)3.5 (0.2)E24H86 (15)1.2 (1.4)135 (74)^a^6.3 (1.4)^a^4.3 (1.4)^a^1.7 (0.8)^a^SE24H85 (18)1.0 (0.3)^b,c^142 (39)7.4 (1.8)3.6 (0.8)2.1 (0.6)^b^VancomycinHS48 (9)0.0 (0)180 (37)12.4 (2.6)2.8 (0.7)4.5 (0.2)E24H52 (10)1.59 (0.9)^a^131 (60)^a^15.7 (3.9)4.0 (1.1)^a^4.0 (0.6)SE24H51 (12)2.2 (0.4)^b^116 (20)^b^19.3 (3.3)^b^3.9 (0.6)^b^4.9 (0.7)^c^GentamicinHS20 (2)0.0 (0)78 (7)13.0 (1.3)3.1 (0.3)4.3 (0.1)E24H12 (6)^a^0.3 (0.3)^a^25 (12)^a^34 (23.5)^a^12.1 (7.4)^a^2.7 (0.5)^a^SE24H16 (2)^b^0.6 (0.2)^b,c^39 (6.5)^b^20.1 (2.9)^b^5.9 (1.0)^b,c^3.5 (0.7)^b,c^MeropenemHS26 (16)0.0 (0.1)71 (45)91.0 (138)20.9 (28)3.9 (0.8)E24H27 (13)0.5 (0.4)36 (26)16.5 (3.0)13.8 (4.9)1.4 (0.9)^a^SE24H29 (7)0.3 (0.1)39 (9.0)19.9 (3.7)13.2 (2.4)1.6 (0.3)^b^DoripenemHS26 (17)0 (0)73 (47)63.8 (83)17.6 (22)3.5 (0.2)E24H30 (6)0 (0)42 (20)17.1 (2.8)13.5 (4.6)1.5 (0.9)^a^SE24H28 (6)0 (0)39 (8)20.2 (3.0)13.1 (2.4)1.6 (0.2)^b^CiprofloxacinHS3.3 (0.5)0 (0)13.6 (1.8)31.9 (4.4)7.2 (0.9)4.5 (0.3)E24H5.1 (1.1)^a^0.1 (0.1)^a^8.3 (1.5)^a^39.0 (7.6)^a^11.8 (2.5)^a^3.5 (1.2)^a^SE24H5.8 (1.2)^b^0.1 (0.1)^b,c^10.2 (1.5)^b,c^52.7 (9.1)^b,c^8.2 (1.2)^c^6.4 (0.5)^b,c^FluconazoleHS7.7 (0.9)0 (0)48.2 (6.2)13.3 (2.2)1.2 (0.3)12.0 (5.8)E24H9.1 (1.2)^a^2.6 (0.8)^d^51.0 (5.0)16.7 (2.8)^a^1.0 (0.3)17.1 (5.5)SE24H9.2 (1.4)^b^2.9 (0.5)^b^52.3 (3.5)17.7 (3.4)^b^0.8 (0.5)^b^33.7 (29)^b^CaspofunginHS5.7 (1.0)0 (0)33.8 (7.3)10.0 (2.5)0.8 (0.1)12.9 (2.6)E24H4.8 (0.8)0.7 (0.2)^a^22.3 (6.6)^a^14.4 (5.0)^a^1.9 (0.4)^a^7.6 (1.9)^a^SE24H4.3 (1.3)^b^0.4 (0.2)^b,c^15.5 (3.7)^b,c^18.8 (8.4)^b^2.8 (0.9)^b,c^7.9 (6.4)^b^*HS* healthy sheep (*n* = 7), *E24H* healthy sheep on extracorporeal membrane oxygenation (*n* = 7), *SE24H* sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (*n* = 6), *AUC* area under the curve, *MRT* mean resident time, *V* ~*ss*~ steady-state volume of distribution, *C* ~*max*~ maximum plasma concentration, *C* ~*min*~ minimum plasma concentration^a^Statistically significant results for E24H group compared with HS group^b^Statistically significant results for SE24H group compared with HS group^c^Statistically significant differences between E24H and SE24H groups

Scatterplots and linear regression of both CL and V~ss~ against logP and PB are presented in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. Table [5](#Tab5){ref-type="table"} shows regression parameters for predicting study drug PK using logP and PB. PB exhibited a weaker negative linear relationship with CL (HS, *p* = 0.01; E24H, *p* \< 0.001; SE24H, *p* \< 0.001) and with V~ss~ (HS, *p* = 0.01; E24H, *p* = 0.004; SE24H, *p* =0.05). Despite an increased CL for more protein-bound study drugs, PB in itself was a predictor of decreased CL in all study groups (Table [5](#Tab5){ref-type="table"}). logP had a strong positive linear relationship with V~ss~ in both E24H and SE24H (*p* \< 0.001) but not in HS (*p* = 0.9). There was no significant association of logP with CL (HS, *p* = 0.55; E24H, *p* = 0.74; SE24H, *p* = 0.24).Fig. 2Scatterplots and regression of clearance against octanol-water partition coefficient and protein binding by groups. Healthy sheep (HS, *n* = 7), healthy sheep on extracorporeal membrane oxygenation (E24H, *n* = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (SE24H, *n* = 6)Fig. 3Scatterplots and regression of steady-state volume of distribution (V~ss~) against octanol-water partition coefficient and protein binding by groups. Healthy sheep (HS, *n* = 7), healthy sheep on extracorporeal membrane oxygenation (E24H, *n* = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (SE24H, *n* = 6)Table 5Linear regression parameters for predicting PK parameters using drug propertiesGroupDependentIndependentMeanLowerUpper*p* ValueHSCLlogP−0.54−2.371.290.556E24HCLlogP−0.12−0.860.620.744SE24HCLlogP−0.41−1.090.280.235HSCLPB−0.13−0.22−0.030.01E24HCLPB−0.08−0.11−0.04*\<*0.001SE24HCLPB−0.07−0.10−0.04*\<*0.001HSV~ss~logP−0.48−8.437.460.903E24HV~ss~logP2.851.733.97*\<*0.001SE24HV~ss~logP3.842.185.50*\<*0.001HSV~ss~PB−0.50−0.92−0.090.017E24HV~ss~PB−0.10−0.17−0.040.004SE24HV~ss~PB−0.10−0.210.000.056*PB* protein binding, *logP* octanol-water partition coefficient (measure of drug lipophilicity)Separate results for each group are presented for healthy sheep (HS, *n* = 7), healthy sheep on extracorporeal membrane oxygenation (E24H, *n* = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (SE24H, *n* = 6) and pharmacokinetic (PK) parameters clearance (CL) and steady-state volume of distribution (V~ss~)

Discussion {#Sec11}
==========

In this study, we systematically investigated the effects of the ECMO circuit on PK in HS and the combined effects of ECMO circuit and critical illness on PK in S-ALI sheep receiving ECMO. In addition, by using antimicrobials with a range of logP and PB, we were also able to investigate the relative contributions of drug, circuit and disease factors influencing PK during ECMO.

There was some expected variability in PK parameters between the groups. Overall, the main findings of the study are that (1) a significant increase in V~ss~ for lipophilic drugs that was observed only in the ECMO sheep and (2) protein-bound drugs exhibited decreased CL and CL was also more significantly reduced in ECMO sheep. These findings are significant, as they conform to PK alterations described in neonates in the clinical ECMO setting and to emerging PK data in adults, and they provide further insights into mechanisms behind these PK alterations.

Although an increase in V~ss~ during ECMO has been described clinically \[[@CR12]\] for many antimicrobial and sedative drugs, the relative contribution of critical illness, circuit and drug factors towards this phenomenon is largely unclear. Systemic inflammation, capillary leak syndrome and hypoproteinaemia during critical illness can result in a significantly increased V~ss~ \[[@CR13]\]. Similarly, sequestration of drugs in ECMO circuits may lead to a further increase in V~ss~. Equally, a reduction in drug CL during critical illness may result from renal and hepatic dysfunction \[[@CR13]\]. This study confirms both these findings. An increase in V~ss~ for lipophilic drugs occurred in both E24H and SE24H but not in HS, clearly highlighting the role of circuit drug sequestration. For all study drugs except ciprofloxacin, we found no significant difference in V~ss~ between the E24H and SE24H groups, hence the additional influence of critical illness, if at all, in increasing V~ss~ was less apparent. The reasons behind a greater V~ss~ seen in the case of ciprofloxacin in the SE24H group relative to the E24H group is probably a result of decreased CL in the SE24H group and may indicate altered hepatic metabolism. It should be noted that there was no biochemical evidence of any significant hepatic dysfunction in our model. Clinicians should consider circuit sequestration and alterations in hepatic function when prescribing lipophilic antibiotics. In patients with presumably preserved hepatic function, lipophilic antibiotics may have to be prescribed in higher doses. These findings need further validation in clinical PK studies.

Even though protein-bound drugs have previously been shown to be sequestered in ECMO circuits under physiologic conditions \[[@CR23]\] with expected increased V~ss~, we observed no significant increase in V~ss~ for these drugs in the present study. However, there was a trend towards increased V~ss~ for protein-bound drugs in the SE24H group. This may have resulted from reduced plasma protein concentrations in the SE24H group. The difference in blood pH between the SE24H and E24H groups was significant and may have affected PB \[[@CR30], [@CR31]\] and circuit sequestration. Given that unbound drug concentrations were not measured, further interpretation of these data is not possible. From a general PK perspective, protein-bound drugs are expected to have a relatively lower V~ss~, and during critical illness and ECMO there is a potential for this to increase due to circuit sequestration and other critical illness--induced PK alterations \[[@CR13]\]. The net increase in V~ss~ in a critically ill patient on ECMO is therefore challenging to predict on the basis of mechanistic studies alone. Clinical population PK studies are therefore indicated.

Decreases in CL of antimicrobial and other drugs during ECMO have been reported in previous clinical studies \[[@CR12]\]. Antimicrobial CL could not be predicted on the basis of logP in the present study, which suggests that the CL for lipophilic drugs may depend largely on critical illness factors and hepatic drug metabolism. Sequestration of drugs in the ECMO circuit by itself is unlikely to play any significant role in reducing CL for lipophilic drugs. However, it should be noted that alterations in hepatic blood flow \[[@CR32]\] and hepatic dysfunction may occur in patients before initiation of ECMO or during ECMO (especially during venoarterial ECMO initiated in patients with severe cardiac failure), which may then adversely affect hepatic metabolism of lipophilic drugs and result in decreased CL. The degree of biochemical hepatic derangement in the SE24H group that received venovenous ECMO for predominant respiratory failure may not have been sufficient to influence metabolism of lipophilic drugs significantly.

Even though protein-bound drugs appeared to have more significantly reduced CL in ECMO sheep in the final model, we observed increased CL in both healthy and critically ill sheep on ECMO for relatively more protein-bound drugs (55 % for vancomycin, 95 % for ceftriaxone and 97 % for caspofungin) compared with HS. Interestingly, these three drugs also demonstrated a trend towards an increased V~ss~ during ECMO, especially in the SE24H group. This is an interesting finding, given that protein-bound drugs have been shown to have a greater propensity for sequestration in ECMO circuits in the ex vivo setting. This relative increase in CL and a trend towards an increased V~ss~ for more protein-bound drugs in ECMO sheep may indicate circuit sequestration. Equally, an increase in plasma unbound fraction of these drugs due to heparin displacement \[[@CR33]\] may also have contributed to increased CL and V~ss~ for these drugs. Although this increased CL was apparent in our ovine ECMO models with relatively preserved renal function, this may be of less significance in critically ill patients with significant renal dysfunction or those on continuous renal replacement therapy (CRRT). For example, no significant impact of ECMO on vancomycin CL was observed in a recent clinical population PK study by Donadello et al. \[[@CR18]\]. The sheep had normal renal function, at least biochemically, as opposed to 7 of 11 patients who received CRRT in the above-mentioned study. This is an important point to note because kidney injury and relatively lower CL for vancomycin achieved on CRRT may have negated an increase in CL during ECMO.

Although ex vivo studies confirm relative stability of vancomycin in ECMO circuits, they do not replicate the in vivo situation. A recent ex vivo study showed that, with drugs with similar PB, lipophilicity becomes the determinant of eventual circuit loss. Vancomycin, although relatively protein-bound (55 %), is hydrophilic. Hence, it is possible that, in the in vivo setting, there is a greater propensity for hydrophilic protein-bound drugs to undergo circuit sequestration. Appropriately powered clinical population PK studies in which investigators compare vancomycin PK in ECMO patients with and without preserved renal function are needed to address this further, and such studies are currently underway \[[@CR34]\].

In summary, sequestration of lipophilic antibiotics plays an important role in increasing their V~ss~ during ECMO. CL of lipophilic drugs is largely dependent on hepatic drug metabolism, which can be significantly affected in a subgroup of ECMO patients receiving venoarterial ECMO for cardiac failure. Although more protein-bound drugs were found to have relatively higher CL in this study, PB in isolation may not be a reliable predictor of CL. Patients on ECMO may have significant renal dysfunction, which is more likely to influence the net CL than sequestration alone. Overall, ECMO appears to decrease antimicrobial CL. These findings need further validation in clinical studies, and such studies are currently underway \[[@CR34]\].

This animal study has limitations. Apart from inherent PK variability that is expected in a small sample, the distribution, metabolism and excretion processes in sheep may differ from those of humans. Despite the SE24H group's development of severe cardiorespiratory failure following S-ALI, the degree of hepatic and renal dysfunction may not have been sufficient to more fully elucidate the full impact of critical illness of PK. However, the changes in PK due to critical illness are very well described, and the use of a model with no advanced end-organ failures that is designed to more fully examine the circuit--drug interactions is justified. Also, this study was directed more at observing relative PK changes between groups and the effects of drug factors logP and PB on antibiotic PK.

Conclusions {#Sec12}
===========

Lipophilic antimicrobial agents are likely to have an increased V~ss~ and decreased CL during ECMO. Protein-bound antibiotics are likely to have reductions in both CL and V~ss~ during ECMO. The strong relationship between logP and V~ss~ during ECMO indicates circuit sequestration of lipophilic drugs. These findings highlight the importance of drug factors in predicting antibiotic drug PK during ECMO and should be a consideration when performing and interpreting population PK studies.

Key messages {#Sec13}
============

Sequestration of lipophilic antibiotics results in increased V~ss~ on ECMO.Lipophilic drugs exhibit a larger V~ss~ during ECMO, and lipophilicity by itself has little impact on drug CL.Protein-bound drugs may have decreased V~ss~ and CL during ECMO.Higher doses of lipophilic antibiotics may be indicated in patients with intact hepatic function.Lipophilicity and PB are useful drug factors to use in predicting antibiotic PK during ECMO.

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

AUC

:   area under the curve

BP

:   blood pressure

CL

:   clearance

C~max~

:   maximum plasma concentration

C~min~

:   minimum plasma concentration

CCO

:   continuous cardiac output

CRRT

:   continuous renal replacement therapy

ctHb

:   concentration of total blood haemoglobin

CVP

:   central venous pressure

E24H

:   healthy sheep on extracorporeal membrane oxygenation

ECLS

:   extracorporeal life support

ECMO

:   extracorporeal membrane oxygenation

FiO~2~

:   fraction of inspired oxygen

HPLC

:   high-performance liquid chromatography

HS

:   healthy sheep

ICE

:   intra-cardiac echocardiography

ICU

:   intensive care unit

IJV

:   internal jugular vein

IV

:   intravenous

logP

:   octanol-water partition coefficient

MRT

:   mean resident time

paCO~2~

:   partial pressure of carbon dioxide

paO~2~

:   partial pressure of oxygen

PAP

:   pulmonary arterial pressure

PB

:   protein binding

PEEP

:   positive end-expiratory pressure

PK

:   pharmacokinetic(s)

S-ALI

:   smoke inhalation acute lung injury

SE24H

:   sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation

SvO~2~

:   mixed venous oxygen saturation

V~ss~

:   steady-state volume of distribution

V~T~

:   tidal volume

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

KS designed the study and wrote the draft study protocol, wrote grant applications to support drug assays, analysed data and wrote the draft manuscript. JAR assisted with protocol development and edited and critically evaluated the manuscript. JFF and YLF led the team that wrote the grant to secure funding for the animal ECMO experiment. JFF, YLF, SD and KS developed the animal model with assistance from many other research team members listed in the Acknowledgements section. AGB assisted with statistical and PK analysis. SCW carried out antibiotic drug assays. AGB, SD, JFF, SCW and YLF edited and critically evaluated the manuscript. All authors read and approved the final manuscript.

The authors acknowledge Lynnette Munck, Kimble R Dunster, Margaret Passmore, Gabriella Simonova, Charles McDonald, Sam Foley and Suzanne Parker for assistance with the study. This work was supported in part by funding provided by the National Health and Medical Research Council, the Australian and New Zealand College of Anaesthetists, the Intensive Care Foundation and the Prince Charles Hospital Foundation. JAR is funded by a National Health and Medical Research Council of Australia Training Research Fellowship (409931). JFF currently holds a Health Research Fellowship awarded by the Office of Health and Medical Research, Queensland, Australia.
